This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Takahashi et al. have reported on the benefit of IV immunoglobulin (IVIg) in five patients with long-standing ataxic sensory neuronopathy with Sjögren syndrome (SSASN).1 We would like to report a similar experience in two siblings with SSASN.
A 62-year-old woman presented with a 1-year history of progressive sensory symptoms with prominent ataxia causing marked gait difficulty, associated with dryness of eyes and mouth (sicca complex) and 40-pound weight loss. Her examination was remarkable for a moderate-to-severe sensory-motor polyneuropathy, with positive Romberg sign and wide-based, ataxic gait.
Her 69-year-old brother reported a 5-year history of progressive stocking-glove distribution sensory symptoms. His examination similarly revealed findings of sensory-motor polyneuropathy, with marked ataxia and positive Romberg sign.
Prominent lymphocytic infiltration was seen on salivary gland biopsy of both patients. Electrodiagnostic testing demonstrated a predominantly axonal sensorimotor polyneuropathy. The sister had elevated SS-A and SS-B antibodies, but the brother did not. The sister’s sural nerve biopsy demonstrated prominent perivascular inflammation of small epineurial vessels and multifocal myelinated nerve fiber loss.
They were treated with IVIg 2 g/kg total dose over 5 days followed by 0.4 g/kg every 3 weeks (sister) or every week (brother). After 3 months of treatment, there was unequivocal improvement in sensory symptoms and dramatic improvement in gait …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Alert Me
Recommended articles
Dominant T-cell clones of unknown significance in patients with idiopathic sensory neuropathies
The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy
Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease
Ataxic vs painful form of paraneoplastic neuropathy